Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone in Duchenne muscular dystrophy patients receiving glucocorticoids
2016-000602-10Phase 3Terminated
- Sponsor
- Santhera Pharmaceuticals
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Idebenone with Placebo (2 arms). Primary endpoint: Change in FVC percent predicted. Started May 2016; status: terminated.
02
Drugs
idebenone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2016-000602-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000602-10.